Browse News
Filter News
Found 95 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 28, 2024
3/28/2024
Pyxis Oncology, Inc. reported that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired employee.
-
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
3/26/2024
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, today announced the closing of its previously announced merger with a wholly-owned subsidiary of AgeX Therapeutics, Inc.
-
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
3/21/2024
Innate Pharma SA reported its consolidated financial results for the year ending December 31, 2023.
-
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
3/20/2024
BioNTech SE announced that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
-
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
3/18/2024
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023.
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
3/5/2024
Akari Therapeutics, Plc and Peak Bio Inc. announce a definitive agreement to merge as equals in an all-stock transaction.
-
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
3/5/2024
Akari Therapeutics, Plc and Peak Bio Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction.
-
Plus, last week Richard Gonzalez announced his retirement from AbbVie, PhRMA appointed Gilead’s O’Day to chair its board and Joseph Papa became president and CEO of Emergent.
-
Medicare Coverage Significantly Expanded for the Eversense E3 CGM System - February 12, 2024
2/12/2024
Ascensia Diabetes Care today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
-
DNA Nanobots Closes Pre-seed Investment Round to Grow BioPharma Partner Program
1/24/2024
DNA Nanobots, a leader in the design and delivery of DNA nanoparticles engineered for targeted therapeutics, announced that it has closed its pre-seed funding round.
-
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings
1/8/2024
NightHawk Biosciences today announced that it is changing the name of the Company to Scorpius Holdings, Inc. (“Scorpius”) to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO.
-
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
12/20/2023
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) today announces additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.
-
1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director
12/19/2023
1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors.
-
SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2024 San Antonio Breast Cancer Conference and US Clinical Trial Developments
12/5/2023
SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of the HER2-specific HIRE platform ADC, BL-M07D1, in the Investigational New Drug (IND) application on November 28, 2023.
-
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
11/10/2023
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a corporate update.
-
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
11/2/2023
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
-
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
10/5/2023
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) today announced positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.